Acceleris Capital portfolio company Reacta Biotech has completed its largest funding round to date, involving £1.25m of equity finance, with further investment expected in the coming months.  Reacta is a Deeside-based biotechnology company producing diagnostic kits for food allergy.  Cases of food allergy and allergy-related hospitalisations continue to rise globally at an alarming rate.  Reacta’s core focus is to improve the diagnosis and management of allergies through the provision of a pharmaceutical grade Oral Food Challenge (OFC), the gold standard for the clinical testing of food allergy.